Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2013

View Archived Issues

Results reported for volasertib plus low-dose cytarabine therapy in AML patients

Alize Pharma launches collaborative research program for AZP-531

Chroma receives milestone payment from GSK for HDAC inhibitor

Tumor-suppressing MAb demonstrates preclinical antitumor efficacy

BRD-9876 identified as potential therapeutic candidate in niche-based screening

Novel guanylate cyclase activators disclosed by Astellas Pharma

U.S. researchers present new protein kinase inhibitors

Receptos patents new GLP-1 receptor modulators

New pegylated nitroimidazole conjugates divulged by researchers in the U.S. and Taiwan

Novel DGAT1 inhibitors synthesized at Daiichi Sankyo

University of Tokushima discloses novel anticancer compounds

New MISRII antibodies presented by The Fox Chase Cancer Center

Swiss and U.S. scientists patent new agents for malaria and toxoplasmosis

Updated results presented from the GAUSS trial of AMG-145

Microbiotix enters licensing agreement for MBX-700 and MBX-701

TheraVida reports topline Tolenix data in overactive bladder and urinary incontinence

NGM signs agreement with Janssen for novel therapeutics for diabetes

Zogenix reports data from phase I Relday trial

FDA approves next-generation Xience Xpedition drug eluting stent system

PharmaEngine and BeBetter enter oncology collaboration

EPIRUS' BOW-015 shows bioequivalence to Remicade in phase I study

Phase I trial of mibefradil for cancer completed

Repligen and Pfizer sign worldwide licensing agreement for spinal muscular atrophy

Biogen's phase III trial of dexpramipexole in ALS fails to meet endpoints

Second phase IIa study of Z-160 begins for chronic neuropathic pain

Celtaxsys commences first-in-human study of treatment for pulmonary inflammation

Alnylam files application for phase I study of RNAi therapeutic in the U.K.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...